Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mapracorat

Drug Profile

Mapracorat

Alternative Names: BAY-865319; BOL-303242-X; ZK-245186

Latest Information Update: 28 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bausch & Lomb; Bayer HealthCare Pharmaceuticals
  • Class Anti-inflammatories; Corticosteroids; Skin disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Psoriasis
  • Discontinued Allergic conjunctivitis; Atopic dermatitis; Dry eyes; Ocular inflammation; Ocular pain

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Psoriasis in Germany (Topical, Ointment)
  • 31 Aug 2013 Bausch & Lomb completes a phase III trial in Ocular pain & inflammation in USA (NCT01591161)
  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top